Potential offtaker

Novo Nordisk A/S

www.novonordisk.com

N/A
N/A
Which other companies from Denmark are actively involved in decarbonization initiatives?
  • Carlsberg Group
  • Norican Group
  • Solar A/S
  • MATAS A/S
  • Novozymes A/S
  • Semler Gruppen
  • Novo Nordisk A/S is a Danish multinational pharmaceutical company that operates in the Large Pharma sector. The company is headquartered in Bagsværd, Denmark, and has a presence in over 80 countries worldwide. Novo Nordisk is primarily known for its diabetes care products, but it also develops and manufactures products in other therapeutic areas such as obesity, haemophilia, and growth hormone therapy.

    Decarbonisation is a key priority for Novo Nordisk, and the company has set ambitious targets to reduce its carbon footprint. In 2020, Novo Nordisk announced its commitment to achieve zero carbon emissions from its operations and transportation by 2030. To achieve this goal, the company is focusing on energy efficiency, renewable energy, and decarbonisation of its supply chain.

    Corporate energy is another area of focus for Novo Nordisk. The company has implemented a range of energy-saving measures across its operations, including the installation of energy-efficient lighting and HVAC systems, and the use of renewable energy sources such as solar and wind power. Novo Nordisk has also implemented a corporate energy management system to monitor and optimize its energy use.

    Corporate power purchase agreements (PPAs) are a key part of Novo Nordisk's renewable energy strategy. The company has signed several long-term PPAs with renewable energy providers to secure a reliable and cost-effective source of renewable energy. In 2020, Novo Nordisk signed a 10-year PPA with Danish energy company Ørsted for the supply of renewable electricity from a new offshore wind farm in the North Sea.

    Renewable energy is a central part of Novo Nordisk's sustainability strategy. The company has set a target to source 100% of its electricity from renewable sources by 2020, and it has already achieved this goal. Novo Nordisk is now working to increase the proportion of renewable energy in its overall energy mix, with a goal to source 50% of its total energy from renewable sources by 2025.

    In addition to its focus on decarbonisation and renewable energy, Novo Nordisk is also committed to reducing its water consumption and waste generation. The company has implemented a range of measures to reduce its water use, including the installation of water-efficient equipment and the reuse of wastewater. Novo Nordisk has also implemented a waste management system to reduce its waste generation and increase recycling.

    Novo Nordisk is committed to sustainability and has been recognized for its efforts in this area. The company has been included in the Dow Jones Sustainability Index for 19 consecutive years and has been named one of the world's most sustainable companies by Corporate Knights. Novo Nordisk has also been recognized for its efforts to promote gender equality and diversity in the workplace.

    In conclusion, Novo Nordisk A/S is a Danish multinational pharmaceutical company that operates in the Large Pharma sector. The company is committed to sustainability and has set ambitious targets to reduce its carbon footprint, increase its use of renewable energy, and reduce its water consumption and waste generation. Novo Nordisk is a leader in corporate energy management and has implemented a range of measures to increase energy efficiency and use renewable energy sources. The company's focus on sustainability has been recognized by industry experts, and it is a leader in promoting gender equality and diversity in the workplace.

    ✓ Current offtaker under Corporate PPA's
    ✓ Re100 Gold member
    ✓ Science Based Targets member
    ✓ Declared Net Zero commitment
    Decarbonization Pathways for Manufacture of basic pharmaceutical products: An Analysis

    Which companies in the industry of Manufacture of basic pharmaceutical products have made significant pledges or efforts to address global warming?
  • Grupo Ferrer Internacional SA
  • Taiho Pharmaceutical Co. Ltd.
  • Ono Pharmaceutical Co.
  • Sanofi
  • Alchem International Private Limited
  • Chiesi Group